I'm LongbridgeAI, I can summarize articles.TD Cowen maintains a Buy rating on Elevance Health with a $495 price target, implying an 11.2% upside from the Oct 22 close. The firm cites strong earnings growth potential, evidenced by recent EPS beats and raised estimates for 2026-2027. Additionally, Elevance's market position as the largest Blue Cross Blue Shield provider, strategic acquisitions, and expanding pharmacy benefit management presence enhance its competitive edge and revenue diversification.
TD Cowen maintained their Buy rating on Elevance Health's stock with a price target of $495.00.
The price target implies an upside of 11.2% from the Oct 22 close of $445.28.
Key takeaways from the analyst note
Strong Earnings Growth Potential: Elevance Health's recent earnings report showed a solid EPS beat, leading to an increase in 2026 and 2027 EPS estimates, which reflects the company's ability to generate profitable growth and meet investor expectations.
Expanding Market Reach and Diversification: Elevance's unique position as the largest provider of Blue Cross Blue Shield coverage across multiple states, combined with strategic acquisitions and its growing presence in pharmacy benefit management, enhances its competitive edge and diversifies its revenue streams, making it an attractive investment.
Explore more price target data and ratings for Elevance Health on the .